Neuroimmunotoxicology: Humoral Assessment of Neurotoxicity and Autoimmune Mechanisms

Hassan A.N. El-Fawal,1,2 Stacey J. Waterman,2 Anthony De Feo,1,2 and Magdy Y. Shamy3

1Pharmacology and Toxicology Laboratory, Mercy College, Dobbs Ferry, New York USA; 2New York University Institute of Environmental Medicine, Tuxedo, New York USA; 3High Institute of Public Health, University of Alexandria, Alexandria, Egypt

The interactions between the nervous and immune systems have been recognized in the development of neurodegenerative disease. This can be exploited through detection of the immune response to autoantigens in assessing the neurotoxicity of environmental chemicals. To test this hypothesis, the following questions were addressed. a) Are autoantibodies to nervous system (NS) antigens detected in populations exposed to environmental or occupational chemicals? In sera of male workers exposed to lead or mercury, autoantibodies, primarily IgG, to neuronal cytoskeletal proteins, neurofilaments (NFs), and myelin basic protein (MBP) were prevalent. These findings were confirmed in mice and rats exposed to either metal. b) Do autoantibodies to NS antigens relate to indices of exposure? In humans exposed to either metal, and similarly in exposed rats, titers of IgG against NFs and MBP significantly correlated with blood lead or urinary mercury, the typical indices of exposure. c) Do autoantibodies correlate with sensorimotor deficits? In workers exposed to lead or mercury, a significant correlation was observed between IgG titers and subclinical deficits. Doses of metals used in rat exposures were subclinical, suggesting that autoantibodies may be predictive of neurotoxicity. d) Is the detection indicative of nervous system pathology? In rats exposed to metals, histopathology indicated central nervous system (CNS) and peripheral nervous system (PNS) damage. In addition there was evidence of astrogliosis, which is indicative of neuronal damage in the CNS, and the presence of IgG concentrated along the blood-brain barrier, as indicated by immunostaining for antibodies. e) Are immune responses to NS antigens pathogenic? Immunoglobulin fractions from rat and human sera interfered with neuromuscular function. These studies suggest that the detection of autoantibodies to NS-specific antigens may be used to monitor the development of neurotoxicity to environmental chemicals and that immune mechanisms may be involved in the progression of neurodegeneration. Key words: autoantibodies, autoimmunity, biomarkers, heavy metals, neurodegeneration, neuropathology, risk assessment. — Environ Health Perspect 107(suppl 5):767–775 (1999).

http://ehpnet1.niehs.nih.gov/docs/1999/suppl-5/767-775elf-fawal/abstract.html

The inaccessibility of the nervous system has long posed a challenge to neuroscientists and in particular to neurotoxicologists. This inaccessibility has impeded the evaluation of cellular and molecular changes associated with the initial changes of neurotoxicity, prior to overt clinical deficits in live animals and humans. Current methods of assessing the development of and recovery from neurotoxic insult include behavioral, electrophysiologic, and brain imaging techniques (1,2). However, these evaluations require highly trained personnel, are costly, and do not identify specific cellular substrates or mechanisms. This imposes limitations to their utility in clinical diagnostics, risk assessment, and their applicability to populations in the exposure arena (e.g., agriculture, industry). Furthermore, the detection of deficits often does not occur in the absence of overt manifestations.

O’Callaghan (3,4) has proposed that neurotropic and glialtropic proteins be used to detect and characterize the cellular response to toxicant-induced injury. Alterations in nervous system-specific proteins; for example, gial fibroillar acid protein (GFAP), the astrocytic intermediate filament, may be expressed at low exposure levels of neurotoxic metals and toluene (3,5–7) and other nervous system insulins. This reactive gliosis occurs secondary to neuronal insult and degeneration. Although direct measurement of proteins in the brain may provide valuable insights into the cellular targets of neurotoxicity in animal studies (3,8,9), they are not applicable to human populations. However, this evidence should prove invaluable in evaluating potential biomarkers of neurotoxicity.

We have proposed that exposure to neurotoxic agents and the attendant neurodegeneration with the liberation of neural proteins can induce an autoimmune response conveniently measurable in blood. This immune response is reflected in the production of serum autoantibodies against nervous system proteins and activation of lymphocytes. Surprisingly, few neurotoxicology studies have investigated the possible involvement of the immune system and autoimmunity as a marker or as an effector in the development of neurotoxicity.

Neurocytology, Immunology, and Immunoprivilege

It is well established that the nervous system comprises the heterogeneous cell populations. Neurons, the excitable elements of the nervous system, are considered synonymous with nervous system function. These are the cells responsible for detecting intrinsic and extrinsic environmental stimuli (sensory function), communicating these stimuli for interpretation (brain and spinal cord function), and formulating appropriate responses to these stimuli (motor function). Despite their being the minority cells of the nervous system, neurons control and regulate body function, thus placing them in a unique position of vulnerability. Neuroglia, astrocytes, oligodendrocytes, Schwann cells, and microglia are the majority cells. Functionally they provide protection, influencing electrical conductive properties of the neuronal axons and dendrites. Astrocytes, Schwann cells, and central macrophages (microglia), however, may play a role in immune activation within the nervous system.

Astrocytes may play a role in the regulation of inflammation and immune responses in the central nervous system (10). Astrocytes release interleukin (IL)-1 in response to substance P stimulation (11) and produce tumor necrosis factor (TNF)-α in response to viral infection (12,13) and bacterial lipopolysaccharide (LPS) (14). Viral or LPS stimulation induce the gene expression of IL-1α; IL-1β; IL-6, and interferon (IFN)-γ by astrocytes (12). Astrocytes also secrete IL-3, which induces microglial proliferation (15,16), suggesting a cooperative role between astrocytes and microglia during cell injury. Astrocytes also produce complement factors C3 and B (17). Astrocytes not only produce cytokines and complement factors but also respond to cytokine stimulation. Human astrocytes proliferate in response to TNF-α. This is accompanied by downregulation of GFAP expression (18). Stimulation of murine and human astrocytes by...
IFN-γ enhances their expression of class II major histocompatibility complex (MHC) (19,20). Astroglisosis, the astrocytic proliferative response to neuronal injury, may be in response to IFN-γ (21), whereas it is down-regulated by IL-4 (22).

Although astrocytes may not act as the major antigen-presenting cells (APCs), microglia act as APCs in the brain. These are among the first cells to be recruited in response to injury (23). In turn, microglia may stimulate astrocytes following injury through the production of TNF-α, IL-1β, and IL-6 (23,24–26). The proliferation and APC activity of microglia has been shown to be stimulated by IFN-γ, colony-stimulating factor of macrophages (16,27,28). Microglia express both MHC I and MHC II, indicating their immunocompetence (29). Expression of both MHC I and II suggests that microglia may stimulate both T-helper (Th) and cytotoxic T cells (30).

Similarly, in the peripheral nervous system (PNS), Schwann cells respond in vivo and in vitro to IFN-γ and TNF and express MHC I and II (31,32). This ability of myelinating Schwann cells to act as APCs has been documented following peripheral nerve crush and in peripheral nerve disease (33,34).

Under normal circumstances, the nervous systems, both central and peripheral, are considered relatively immunoprivileged, as provided by the blood–brain barrier (BBB) and blood–nerve barrier (BNB). The BBB consists of specialized endothelial cells with tight junctions, pericytes, and bone marrow-derived perivascular elements. These are enclosed within a basal lamina and astrocyte foot processes (35). On the other hand, the BNB is formed by the permeable epineurium, the tight junctions of the perineurium, and the impermeable endoneurium (35). These barriers control the selective entry of essential biomolecules, including glucose, and exclude potentially harmful elements, including immune cells. However, this immunoprivileged status may be lost as a result of nervous system injury.

Interactions between Nervous and Immune Systems

As mentioned above, evidence has accumulated that glial cells (astrocytes, microglia, and Schwann in the periphery) play more than structural roles in the nervous system (36,37). Can these cells, or their constituents activate immune cells? GFAP (38) and myelin basic protein (MBP) (39) are mitogenic to cultured lymphocytes, in vitro. MBP is also mitogenic to cultured glia and lymphocytes. This evidence suggests that nervous system proteins may activate lymphocyte following demyelination or glial cell damage. It has now become accepted that interactions and similarities exist between the nervous and immune systems (10,40).

Consistent with the possible role of glial cells as APCs are reports of lymphocyte infiltration across the BBB following its disruption (41,42) or if frank damage is absent, by adhesion to endothelial cells of the BBB (43–45). This adhesion and infiltration is modulated by intercellular adhesion molecule-1 and by cytokines. The presence of T and B lymphocytes in nervous system tissues and cerebral spinal fluid (CSF) has been documented in humans (e.g., multiple sclerosis [MS]) and in experimental models of nervous system disease (46,47). Experimental evidence indicates that activated T-lymphocytes are capable of entry into the central nervous system (CNS) without a need for antigen-specific activation (48), and that the CNS is constantly patrolled by a low but consistent number of activated T-lymphocytes and monocytes. This potential interaction between cells of the nervous and immune systems may have implications for the neurotoxicity of environmental and occupational toxins.

Autoimmune Responses and Neurodegeneration

Autoimmune mechanisms have been recognized in neurologic diseases such as myasthenia gravis (49), Guillain-Barre syndrome (50), and experimental allergic encephalomyelitis (51). The nervous system itself may have immunologic functions as noted earlier (36,52). How nervous system antigens encounter and interact with cells of the systemic and lymphatic circulations and whether this occurs in situ in the nervous system or the periphery is not fully understood. This may occur in the brain parenchyma, in the cervical lymph nodes, excretion through the CSF, or at the BBB (53). The presence of nervous system antigens, GFAP and MBP in particular, has been documented in CSF of adults and children suffering from neurologic diseases, e.g., Alzheimer’s disease and encephalitis (54–60). However, assay of these proteins in peripheral blood as markers of neurotoxic insult may be of limited use in the presence of extracellular proteases. On the other hand, autoantibodies against neurofilament triplet proteins (NFs) as well as MBP and GFAP have been detected in sera and CSF of human subjects suffering from neurologic disorders, including Alzheimer’s disease, Parkinson’s disease, amytrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease, and kuru (61–67). Furthermore, autoantibodies to neurotypic proteins have been demonstrated in animal models of allergic encephalomyelitis and electroconvulsive shock (68,69). The interaction of environmental chemicals, neurodegeneration, and autoimmune responses has yet to be delineated.

Neurotoxic Exposures and Neuroimmune Interactions

As early as 1850, Aran (70) described a progressive muscular atrophy, today known as ALS (motor neuron disease). This was associated with occupational exposure to inorganic lead in some of his patients. Since then, several studies have reported similar observations with elevated levels of lead in plasma, erythrocytes, CSF, and spinal cords of ALS patients (71–74). Similarly, elevated mercury has been reported in patients with ALS (72,75,76). Heavy metals exposure has also been suspected of playing a role in the etiology of MS (77–80). In both ALS and MS, autoantibodies against nervous system proteins are detected. For example, autoimmune antibodies against NFs, MBP, GFAP, and GM1 ganglioside have been detected in sera and CSF of human subjects suffering from these diseases (81–83). Anti-MBP antibodies are cytotoxic and are believed to play a key role in the pathogenesis of MS (65,81). More recently the presence of autoantibodies to the dihydropyridine calcium channel (the L channel) has been demonstrated in sera of ALS and Lambert-Eaton syndrome patients (82). These autoantibody titers correlated with disease progression. Such autoantibodies are pathogenic, interfering with nerve conduction, synaptogenesis, and neurite growth (83–85).

A role for environmental toxicants, particularly metals, in the development of nervous system pathologies and the possible involvement of the immune system are consistent with the experimental observations that metals, particularly lead, augment immune responses. For example, lead enhances B-lymphocyte differentiation in vitro. In vivo it enhances the activity of B lymphocytes toward T-cell–dependent antigens (86–89) and enhances the production of antibody in vivo, as well as directly activating B cells (90). Lead also enhances the production and release of IL-2 from T lymphocytes (91), thus enhancing B-cell responsiveness (90). These observations have led to the suggestion that lead exposure may result in an autoimmune response (90). Highly relevant to the presence of autoantibodies are studies indicating that low levels of lead enhance immunoglobulin synthesis (86,92). In the presence of chemical-induced nervous system degeneration and continued exposure to these chemicals, we believe that lymphocytes can be stimulated to increase autoantibody production. Several studies have demonstrated an increase in serum immunoglobulins following exposure to mercury and lead (93). This increase in serum immunoglobulins may reflect the appearance of autoantibodies.
Neuropathies and Cellular Antigens

Spencer and Schaumburg (94) and Chang (95) have suggested a unifying classification scheme for toxicant-induced neuropathy based on the primary site of insult and the subsequent secondary targets involved. These categories include the following: a) Neuronopathy, where the soma (cell body) is the primary target, followed by secondary nerve fiber degeneration (dying-forward), tertiary myelin loss, and target cell atrophy or death (trans-synaptic degeneration). Neuronopathies are irreversible since neurons are terminally differentiated. Agents such as mercury, aluminum, and glutamate-induced excitotoxicity are believed to precipitate this type of insult. b) Axonopathies, where the axons (or peripheral sensory fibers) primarily targeted are believed to be the most common nervous system injury, particularly the exposed vulnerable peripheral nerves. Axonopathies may progress proximo-distally from the soma or die-back, progressing to a neuronopathy. Secondarily, axonopathies are associated with secondary myelin degeneration in severe cases. Where the soma remains functionally intact, chromatolysis and fiber degeneration may occur. Toxicants inducing axonopathies include acrylamide, hexacarbons, and tri-o-cresyl phosphate. c) Myelinopathies, or myelin glialopathy, involve either the myelin sheath, such as in the case of triethyltin, or the myelinating cells, such as in the case of ethidium bromide neurotoxicity. This may or may not be followed by axonal degeneration. Less well classified is the damage that may occur to astrocytes. It is suggested that astrocytes may be primarily or secondarily targeted by some neurotoxic agents.

In the nervous system, astrocytes act as sites of deposition for heavy metals, including mercury (96,97) and lead (98,99), where these metals may modulate metabolic function (100,101). In this regard, astrocytes may themselves be targets of lead and mercury, resulting in their degeneration and death, whether as a primary target or secondary to astrogliosis (102–106). Similarly, other chemicals may induce damage to glia. Pilocarpine-induced epilepsy in rats resulted in glial damage within the substantia nigra and basal cortex (107). Recently, toluene inhalation has been reported to result in a reduction in the astrocyte-specific protein GFAP (7). Additionally, some chemicals may induce a vasculopathy, resulting in leakage of barriers. Inorganic lead and cadmium fall within this category (94).

On the basis of this classification, we propose that detection of immune responses to autoantigens characteristic of different target sites may be used in identifying the effects and specific targets of the neurotoxic chemicals. Coupled with neuropathologic assessment, these autoimmune responses can be validated for experimental animal studies and the monitoring of human populations. A summary of potential cellular targets and cellular antigens in the nervous system is presented in Figure 1. Additional nervous system-specific proteins are discussed by O'Callaghan (4) and Lintington and Brostoff (107).

Autoantibodies as Markers of Nervous System Injury: Rationale and Hypothesis

In our use of the term marker or biomarker, a distinction is made here between markers of exposure and markers of effect. For example, blood lead levels are used to indicate exposure to lead; they do not provide information on the neurotoxicity of lead. It is inferred from historical human and animal studies that a particular blood level is associated with certain symptoms or lesion. Furthermore, this inference is often based on detection of overt toxicity but does not delineate changes that may be early predictors of toxicity. A second distinction is also made here. In the study of the link between environmental chemicals, autoimmunity, and the nervous system, we distinguish between the concept of immunologic biomarkers of neurotoxicity, immune mechanisms of neurotoxicity, and the immunotoxic effects of environmental chemicals. The latter is discussed in other reviews. The concept of using immunologic indicators to reflect environmental exposure-induced damage to other systems derives from the definition of the immune system as a
functional system responsible for surveillance of the host's various organ systems. The immune system provides a unique opportunity for the neurotoxicologist, particularly in the reduction in the number of experimental animals and in clinical toxicology, for assessing the pathologic status of other systems. This is facilitated by the relatively noninvasive sampling and collection of sera and immune cells. Although this approach has been used successfully by toxicologists in the study of other systems [reviewed in (108–112)], a review of the literature reveals a paucity of studies dealing with neurotoxic exposures and autoimmune responses (113).

The generation of autoantibodies to nervous system-specific antigens is feasible in the presence of neuronal death, axonal degeneration, demyelination, and glial death such as that precipitated by neurotoxic agents in the CNS or PNS. This exposes and liberates intracellular antigens, often sequestered antigens that the immune system has not encountered previously. Our hypothesis is summarized in Figure 2. Proteins specific to nervous system structures would be presented as autoantigens by resident microglia in the CNS or as infiltrating macrophages in the PNS. This would result in a cellular and/or humoral response with autoantibodies raised against these autoantigens in the latter case. The generation of these autoantibodies would likely occur, particularly with metal intoxication, in light of their ability to compromise blood barriers (103,104,114,115). In this way, the immune system provides a means whereby cellular damage in the nervous system can be documented and measured in serum, thereby eliminating the problems associated with the inaccessibility of the nervous system.

**Autoantibodies in Humans and Animals Exposed to Neurotoxic Agents**

The use of autoantibody detection to indicate nervous system insult was tested in our laboratory in several populations and verified in animal studies (Table 1). To illustrate the utility of these assays, we will concentrate on results obtained from inorganic lead exposure.

**Autoantibodies and Exposure**

Field testing of autoantibody assays was performed by our laboratory in male workers occupationally exposed to lead at a battery factory (blood lead: 10–40 µg/dL) or mercury vapor (urinary mercury: 6–30 µg/g creatine) at a fluorescent light factory. In addition, a reference group from a frozen food packing plant with no prior work history of exposure to either metal was also recruited (116–118). All participants in the study were matched on the basis of demographics and socioeconomic status as well as on years of metal exposure. Ambient mercury (as vapor) and lead (as dust or fumes), 0.05 and 0.09 mg/m³, respectively, are below or at the threshold limit value–time weighted average (TLV-TWA) adopted by the American Conference of Governmental Industrial Hygienists.

Titters of autoantibodies (IgM and IgG isotypes) to NF proteins NF-68, NF-160, and NF-200; GFAP and MBPs were determined.

---

**Figure 2.** Hypothesis for the induction and pathogenesis of autoantibodies to nervous system proteins during exposure to environmental chemicals. Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; APC, antigen-presenting cells; B, B lymphocyte; BBB, blood–brain barrier; BNB, blood–nerve barrier; CNS, central nervous system; IL, interleukin; NF, nervous system protein; PNS, peripheral nervous system; T, T lymphocyte; Y, antibody. Following the initial insult (1) by neurotoxic chemical to cells of the nervous system, autoantigens (NP) see Figure 1) are released and (2) undergo antigen processing and presentation by microglia, or astrocytes or macrophages. (3) This results in T-lymphocyte activation and stimulation of B lymphocytes by interleukin signaling (e.g., IL-6 and IL-2) to produce autoantibodies to these autoantigens. This may occur in situ within the nervous system or as a result of being extruded into the peripheral circulation. The perception that these antibodies are foreign is facilitated by the presence of BBB and BNB. In addition, environmental chemicals may act directly on the immune system to augment the development of cellular or humoral responses. (4) Autoantibodies (Y) may be pathogenic, contributing to the progression of the neuropathology or physiologic impairment. Autoantibodies may directly induce damage to neurons or compromise function by complexing to surface antigens, fix-complement to precipitate neuronal death, or damage neural tissue by ADCC.

| Exposure | Medium | Species | Reference |
|----------|--------|---------|-----------|
| Phenyl saligenin phosphate (po) | Serum | CBA/J mice | (123) |
| Lead acetate in drinking water | Serum | ALAD mice | (165,166) |
| Lead acetate in drinking water | Serum | Fischer 344 | (120,123) |
| Trimethyl lead | Serum | Fischer 344 | (169) |
| Methyl mercury in drinking water | Serum | Fischer 344 | (121) |
| Cadmium chloride (po) | Serum | Fischer 344 | (171) |
| Trimethyl tin (ip) | Serum | Long Evans | (171) |
| Cobalt | Serum | Sprague-Dawley | (170) |
| Trimethyl lead in food | CSF | Macaque | (171) |
| Tolune by inhalation | Serum | Macaque | (171) |
| Cadmium in brain plant | Plasma | Human | (172) |
| Lead in battery plant | Serum | Human | (113,116,117) |
| Mercury in fluorescent light plant | Serum | Human | (113,118) |
| Tetrachloroethylene and solvents | Serum | Human | (170) |
| Methamidophos | Serum | Human | (173) |
| Pesticide mixtures | Serum | Human | (174) |

Abbreviations: CSF, cerebral spinal fluid; ip, intraperitoneal; po, per os.
in sera of exposed and reference populations by an enzyme-linked immunoassay developed by El-Fawal et al. (119) against these proteins. Summaries of individual titers, the mean, and the percent of each population with detectable immunoglobulins (M and G isotypes) against NF-68 in all three populations are presented in Figure 3. Autoantibodies against neuroproteins predominated in metal-exposed populations compared to the reference population. The detection of autoantibodies in a small percentage of the reference population probably reflects natural autoantibodies, usually IgM, which are found in some individuals (G3,120).

The generation of autoantibodies to these antigens during lead or mercury exposure was confirmed (119,121). In studies with lead (121), male Fischer 344 rats (> 42 days of age) were exposed to 50 or 450 ppm lead acetate in the drinking water. No overt signs of toxicity or changes in home-cage behavior (122) were evident in any of the rats. Blood lead levels ranged from 11 to 50 μg/dL and were comparable to those measured in humans. While control rats had no detectable titers to these particular antigens, titers of autoantibodies, particularly IgM, were detected and quantified as early as 4 days after the initiation of lead exposure. IgG was detected later. The detection of anti–NF-68 and the time course are summarized in Figure 4. The early detection of IgM is consistent with a primary antigen challenge (in this case autoantigens). There was significant elevation of IgM titers, followed by a gradual isotype switching to IgG at later durations. In both human and rat studies, autoantibody levels, particularly anti-NFs, correlated significantly with blood lead—the index of exposure for both humans and rats (Table 2).

To confirm the presence of autoreactive B lymphocytes expressing autoantibodies to nervous system proteins, splenocyte preparations from lead-exposed rats and mice (123) were challenged with LPS. Both IgM and IgG against NFs, GFAP, and MBP were detected in the splenic supernatants. Figure 5 shows the IgM response of LPS-stimulated rat splenic cells at 7 days of exposure. In mice, the production of autoantibodies from splenocytes was accompanied by IL-6 and IL-2 production by T lymphocytes (concanavalin A-stimulated cultures). IL-6 is believed to stimulate B-lymphocyte differentiation to antibody-producing plasma cells and copromotes IL-2 production by mature T lymphocytes. IL-2 promotes secretion of antibodies from activated B lymphocytes and is consistent with Th-assisted B-cell responses (102).

**Autoantibodies and Clinical Deficits**

In exposed human populations, antibody titers that significantly correlated with exposure and sensorimotor function were predominantly IgG. IgG is the isotype most commonly associated with secondary antigen challenge or antigen persistence and pathology (124). A significant dose–response relationship between the total number of detectable autoantibodies of the G isotype (IgG score) to the five antigen proteins and the total number of upper and lower limb sensorimotor deficits (clinical score) was observed (Figure 6). This suggests an association between the appearance of antibodies in the sera and the neurotoxicity of metal exposure. However, it must be emphasized that sensorimotor deficits were subclinical and not overt.

**Antibodies and Cellular Targets**

The neuropathology associated with chronic exposures to mercury or lead primarily involves the neuroaxon with secondary demyelination (105,115,125). In the human studies, anti-NFs, IgG isotype, were the most frequently detected antibodies. These were also the antibodies and the isotype best correlated with blood lead or urinary mercury and clinical scores of sensorimotor deficits. This is consistent with the type of neuropathy in humans that manifests primarily neuroaxonal damage. Furthermore, the detection of anti-GFAP titers in these studies supports the targeting of the CNS and astrocytes by heavy metals (96–98), since astrocytes are exclusively found in the CNS. In this manner, autoantibodies may provide a means whereby subcellular targets and the progression of neuropathy may be documented.

In this context the temporal appearance of autoantibodies in serum provides information on the extent of target cell involvement and the progression of insult. For example, it is likely that anti-NF titers would be the first to appear with primary neuronal involvement (e.g., mercury), whereas anti-MBP would precede all others in the case of primary demyelination (triethyltin).

**Toxic Exposures May Precipitate Autoimmunity by Altering Antigen Immunogenicity**

The role of environmental factors in the production or augmentation of autoimmune responses has been suggested for some time. The interaction of drugs or environmental chemicals, including metals (e.g., gold, mercury, and glomerulonephritis), with endogenous protein constituents may alter their immunogenicity and result in the induction of immune responses reflected in the generation of autoantibodies (108). Having detected
antibodies to nervous system antigens in humans and experimental animals, it was speculated that further alteration of these antigens may occur with chronic exposures to neurotoxicants. This may provide a basis for differential antibody profiles between chemicals. Waterman et al. (123,126) have demonstrated that in vitro treatment of the neural antigens NFs, MBP, and GFAP with lead, followed by inoculation of CBA/J mice, resulted in antibody titers that were significantly higher than those produced by the antigens alone. MBP is a negatively charged 18-KD protein with 170 amino acid residues with no sulphydryl groups (127). Lead additions, which are divalent, may bind to two MBP molecules in a charge neutralization process (126) to produce a larger, more immunogenic antigen. In contrast, NFs and GFAP contain methionine and cysteine residues with which metals are known to react (128,129). It is possible that this binding unmasks new epitopes on the autoantigen, rendering it immunogenic or more immunogenic. This provides evidence that a known neurotoxic chemical can alter the immunogenicity of antigen and enhance the magnitude of the autoimmune response. This is significant in light of the suspected involvement of heavy metals in autoimmune neurodegenerative diseases where environmental factors may play a role (see “Neurotoxic Exposures and Neuroimmune Interactions”).

Autoimmune Responses and the Progression of Neurotoxicity

Numerous studies have indicated that autoantibodies may not simply represent an epiphenomenon indicative of tissue damage. Anti-MBP antibodies from MS patients have been shown to be cytotoxic and are believed to play a key role in the pathogenesis of MS (65,81). Antibodies to dihydropropyridine calcium channel (the L channel) from sera of ALS and Lambert-Eaton syndrome patients are pathogenic and interfere with nerve conduction, synaptogenesis, and neurite growth (83,84). Furthermore, recent evidence indicates that autoantibodies do not interact with surface antigens but may penetrate normal cells, including neurons, to produce degeneration and apoptosis (130-132).

We have shown that the immunoglobulin fragment from lead-exposed rats attenuates presynaptic neurotransmission in isolated neuromuscular preparations (Figure 7) (133). It did not, however, block muscle responses postsynaptically, as evidenced by normal responses to exogenously added acetylcholine. Autoantibodies to the presynaptic protein synaptotagmin were detected in these sera. Sera of unexposed rats did not block neurotransmission nor did they contain anti-synaptotagmin antibodies. Synaptotagmin is a calcium-dependent vesicle protein, a component of the docking-fusion pore machinery (134,135). Autoantibodies to this protein or other presynaptic proteins processed following axonal degeneration in sera of lead-exposed rats may interfere with neurotransmitter release. These results are not surprising with metals. Synapses are a major site of mercury neurotoxicity (136-138). Presynaptically, mercury blocks sodium and calcium channels (139). Lead blocks different types of channels (140,141) and interferes with calcium regulatory proteins such as protein kinase C and calmodulin (142,143). In the course of interactions with these target proteins and the ensuing neurodegeneration is an autoimmune response with the potential to subsequently target these neuronal mechanisms possible? This would be consistent with our studies and studies of sera of patients with Lambert-Eaton syndrome where autoantibodies to synaptotagmin, synaxin, the N, P, and Q calcium channels have been detected and shown to interfere with calcium currents and neurotransmitter release (144-151). In contrast, sera from patients with Miller-Fisher syndrome block neuromuscular transmission pre- and postsynaptically (152); sera from ALS patients (153) and diabetic BB/W rats (154) enhance calcium currents and neurotransmitter release.

In contrast to the studies with lead is the enhancement of muscle contractility to electrical stimulation of a nerve–muscle preparation and to exogenous acetylcholine in the presence of immunoglobulin from hens exposed to phenyl saligenin phosphate 21 days earlier (155,156). Sera from these hens contained antibodies to acetylcholinesterase (AChE), which would explain these responses and the inhibition of muscle homogenate.

**Figure 5.** IgM in splenic supernatant following stimulation of rat (n = 7) splenocytes collected from rats 7 days after exposure to 450 ppm lead acetate in the drinking water. Abbreviations: GFAP, glial fibrillary acidic protein; NF, neurofilaments. Splenocytes were cultured for 72 hr with lipopolysaccharide in M199 supplemented with 5% fetal bovine serum. Cell-free supernatants were collected and assayed for autoantibodies to nervous system proteins. For further details see Waterman et al. (126). This verifies the presence of an autoreactive B-lymphocyte population to nervous system proteins. Control splenic supernatants did not have detectable titers of antibodies to these proteins (see text). Each bar represents the mean ± SD.

**Figure 6.** Dose–response relationship between clinical scores and the number of detectable IgG titers against nervous system proteins in reference, lead-exposed, and mercury-exposed humans (n = 129). These data indicate that as more autoantibodies against nervous system proteins are detected the greater the likelihood of clinical deficits due to greater neurotoxicity, p < 0.0001 (see text). Each bar represents the mean ± SD.

**Figure 7.** Sample trace of an isolated neuromuscular preparation twitch response to electrical stimulation of the nerve (acetylcholine release) in the absence (before) and presence (after) of a 150-µL IgG fragment isolated from sera of a rat exposed to 450 ppm lead for 42 days. There was an attenuation of muscle responses in the presence of the immunoglobulin fragment. Sera had detectable titers to nervous system proteins, including synaptotagmin (see text).
AChE by the immunoglobulin fragment of the sera. Pathogenic anti-AChE antibodies have been reported in several neuropathies including ALS (157–160). It should be noted that inhibition of endothelial AChE by antiesterases increases BBB permeability (161). Sera from these hens had detectable autoantibodies to NFs and MBP as early as seven days following exposure. Titters of NF autoantibodies significantly correlated with clinical deficits. This is consistent with the axonopathy known to be associated with some organophosphates.

Immunoglobulins to post synaptic receptors have not yet been identified following neurotoxic exposures but are likely to play a role in neuropathy. This is recognized in myasthenia gravis with autoantibodies to the nicotinic acetylcholine (ACh) receptor (49), antimuscarinic (m)ACH receptor in Chagas disease (162), and anti-β-adrenoreceptors in dilated cardiomyopathy (163,164).

Another pathogenic role for autoantibodies is suggested in experiments by Claudio et al. (165,166). Mice with a duplication of d-aminoolevulinate dehydrase gene (ALAD) when exposed to lead manifested an increase in BBB permeability. These animals had significant autoantibodies to neural proteins, particularly GAP41. Immunohistochemistry of the BBB showed significant presence of IgG at the BBB. This was not observed in control mice or in mice with a single copy of the ALAD gene. This study suggests that increased BBB permeability not only exposes neural epitopes to the immune system, but that immunoglobulins gain access to the CNS. The question of whether these autoimmune responses reflect compromised immunoprivilege is partially answered by the detection of antiserum immunoglobulins in the sera of the same individuals exposed to lead and mercury (167). The blood–brain barrier is believed to serve a function similar to that of the BBB and may be affected by metals.

In addition to the above-described studies, autoantibodies to nervous system proteins have been detected in animals exposed to other inorganic and organic metals or solvents (168–71) and in humans exposed to metals or pesticides (172–74).

Conclusions and Recommendations

The studies discussed in this review illustrate the utility of the immune system's functional status for developing markers of neurotoxic effects of chemicals. They also suggest a role of environmental chemicals in the development of nervous system autoimmunity disease and/or the progression of neuropathy. In the case of the autoantibody assays, these studies suggest a promising association between the appearance of autoimmune titers against nervous system proteins and exposure to subclinical levels of known neurotoxicants. Even if these humoral responses prove to be an epiphenomenon, secondary to nervous system injury, they would be useful indices of this injury. Currently, readily accessible and sensitive markers of neurotoxic insult (i.e., prior to overt changes) do not exist. This would be particularly applicable in efforts to protect children before severe irreversible damage occurs. The studies need to be expanded in terms of their validation with larger populations, delineation of the role of cellular immunity, and the correlation with neuropathology in experimental studies. Furthermore, this approach can be expanded to include other organ systems with characterized organ-specific antigens (e.g., reproductive, cardiovascular, and pulmonary systems). The use of these immunologic indicators to assess organ system integrity following chemical exposure provides a relatively simple, minimally invasive, objective means of documenting pathogenesis in human populations and animal studies. The question of autoimmune mechanisms as they relate to neurotoxicity has only begun to be addressed. Is the immune system a major effecter in the progression of the symptoms associated with chemical-induced neuropathy? This question has only recently been raised, primarily from the work presented here. An unequivocal answer, however, can only be obtained by mechanistically based research addressing this question. Initially, studies of documented neurotoxic agents (e.g., metals, solvents) should be performed to address the involvement of autoimmune interactions in the development of nervous system disease and to distinguish between autoimmune disease as a phenomenon following degeneration and autoimmune disease.  

References and Notes

1. Anger W.K., Assessment of neurotoxicity in humans. In: Neurotoxicology (Tilton H.A., Mitchell C.L., eds). New York: Raven Press, 1992;383–386.
2. Elie AI., Lead neuropathy and electrophysiological studies in low level lead exposure: a critical review. Neurotoxicology 7:203–216 (1986).
3. O Callaghan J.P., Neurotrophic and glial proteins as biochemical markers of neurotoxicity. Neurotoxicol Teratol 10:445–452 (1988).
4. O Callaghan J.P., Assessment of neurotoxicity using assays of neuron and glial-localized proteins: chronology and critique. In: Neurotoxicology (Tilton H.A., Mitchell C.L., eds). New York: Raven Press, 1992;83–100.
5. Evans HL, Jortner BS, El-Fawal HAN. Glial response to trimethyl lead in the macaque monkey (Abstract). Toxicologist 12:312 (1987).
6. El-Fawal HAN, Little AR, Gong Z, Evans HL. Glial response to methylmercury in rat brain: regional- dose- and time-response (Abstract). Toxicologist 12:312 (1987).
7. Little AR, Gong Z, Singh U, El-Fawal H, Evans HL. Decreases in brain glial fibrillary acidic protein (GFAP) are associated with increased serum corticosterone following inhalation exposure to toluene. Neurotoxicology 10:739–747 (1988).
8. Evans HL, Little A, Gong Z, Duffy JS, El-Fawal HAN. Glial fibrillary acidic protein (GFAP) as an index of in vivo exposure to environmental contaminants. Ann NY Acad Sci 642:402–406 (1993).
9. Evans HL, El-Fawal HAN. Increased brain GFAP occurs with behavioral and neuromuscular effects of chronic oral methylmercury neurotoxicity. Neurotoxicology 8:219–220 (1987).
10. Lieberman, A.P., Pitha, PM, Shin, HS, Shin, ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or newborn toxic. Proc Natl Acad Sci USA 86:6346–6352 (1989).
11. Merri, J., Koyanagi, Y., Zuch, J., Thomas, L., Martin, F., Chen, I.S. Induction of interleukin 1 and tumor necrosis factor α in brain cultures of human interferon γ 1. J Virol 66:2217–2225 (1992).
12. Chung IY, Benevente EN. Tumor necrosis factor α production by astrocytes. Induction by lipopolysaccharide, TNF-γ and IL-1β. J Neuroimmunol 9:69–74 (1987).
13. Fierz, W. Fontana A. The role of astrocytes in the interactions between the immune and nervous systems. In: Astrocytes, Vol 3 (Federoff F., Vernadakis A., eds). New York: Academic Press, 1987.
14. Fierz K, Malipiero UV, Leist P. On the cell surface and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 19:689–694 (1989).
15. Levi-Strassou M, Mallet M. Primary cultures of murine astrocytes produce c3 and factor H, two components of the alternative pathway of complement activation. J Immunol 139:2361–2366 (1987).
16. Selmg, K., Shaff-Zagbara A, Bosloch AR, Faustino M, Raines CS, Norton C, Brown JF. Tumor necrosis factor-induced proliferation of astrocytes from mature brain is associated with down regulation of glial fibrillary acidic protein mRNA. J Neurochem 61:323–329 (1991).
17. Barra BP, Zhao SM, Jacobs B, Yen-Lieberman B, Ransohoff RM. Interferon-β impairs induction of HLA-DR antigen expression in cultured human astrocytes. J Neuroimmunol 23:45–53 (1989).
18. Fierz W, Endler B, Reske K, Wokenie H, Fontana A. Astrocytes as antigen presenting cells. Induction of antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 134:3758–3760 (1991).
19. Yang WW, Mountdian R, Yang F, P prejudice T, Freedman MS, Damman N, Antel JP. Interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in vivo. Proc Natl Acad Sci USA 88:7016–7020 (1991).
20. Esteves ML, Iwasaki K, Jacobs BS, Barra BP. Interleukin-4 down regulates adult human astrocyte DNA synthesis and proliferation. Am J Pathol 143:327–341 (1991).
21. Sawada M, Sumizuma A, Maruouchi T. TNF-α induces IL-6 production by astrocytes but not microglia. Brain Res 505:296–299 (1991).
22. Piata Salmi CR. Immunoregulators in the nervous system. Neurosci Behav Rev 15:185–215 (1991).
23. Lee SC, Liu W, Dickson D, Brown CS, Berneman ZW. Cytokine production by human fetal microglia and astrocytes: Differential induction by lipopolysaccharide and IL-1β. J Immunol 150:2059–2067 (1993).
24. Woodroofe MN, Sams DS, Wishaw M, Hayes SM, Loughlin AJ, Tinker A, Cutter ML. Detection of interleukin-1 and interleukin-6 in adult rat brain following mechanical injury by in vivo microdialysis: evidence for a role in microglia cytokine production. J Neuroimmunol 33:227–236 (1991).
25. Sumizuma A, Mazelis SIE, Gontes NK, Silberberg DH. MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of la antigen expression by interferon-γ. J Neuroimmunol 15:263–278 (1987).
26. Raivich G, Gehrmann J, Kreutzberg GW. Increase in macrophage colony stimulating factor and granulocyte-macrophage colony stimulating factor receptors in the regenerating rat facial nucleus. J Neurosci Res 30:862–868 (1991).
27. McGeer MG, Kawamata T, Pollard DG, McGeer PL. Microglia in degenerative neurological disease. Glia 7:84–92 (1993).
28. Akiyama H, Hagihata S, McGeer PL. Major histocompatibility complex antigen expression on rat microglia following epidural laminecotic lesions. J Neurosci Res 20:147–157 (1988).
29. Amato MJ, Pollard JD, Gatenby P, Rat and human Schwann cells in vitro synthesis and express MHC molecules. Muscle Nerve 13:106–116 (1990).
30. Kingston AE, Bergsteindt K, Jensen KF, Van der Meide PH, Cotson MJ, Mirsky R. Schwann cells co-cultured with stimulated T cells and antigen express MHC class II determinants without interferon-γ pretreatment: synergistic effects of interferon and environmental Health Perspectives • Vol 107, Supplement 5 • October 1999 773
EL-FAWAL ET AL.

tumor necrosis factor on MHC II induction. Eur J Immunol 19: 177-191 (1989).
33. Gerebenbauer K, Kingston A, Jessen K.R. Rat Schwann cells can be induced to express MHC class II molecule in vivo J Neurocull 21:382-390 (1992).
34. Weller RO, Ringert RD. U. Changes in plasma cytokines associated with peripheral nerve injury. J Neuroimmunol 39:261-269 (1992).
35. Jacobs JM. Blood-brain and blood-nerve barriers and their relation 

to neurotoxicity. In: Principles of Neurotoxicology (Chang LW, ed), New York-Marcel Dekker, 1994:35-48.
36. Prochnaitz A, Mallat M. Astrocyte diversity. Ann NY Acad Sci 540:52-63 (1989).
37. Hannon SH, Stogrand M, Mollard K. Neurofilament-like pattern 

of reactivity in human foetal PNS and spinal cord following immunostaining with polyclonal anti-glial fibrillary acidic protein antibodies. J Neurocull 18:407-408 (1989).
38. Tanaka J, Nakamura K, Takeda M, Tada K, Suzuki M, Hoita M, Okada T, Hariguchi S, Nishimura T. Enzyme-linked immunosorbent assay for human antirubuloviral to glial acidic fibrillary acidic protein. I. Enzyme assay for human antirubuloviral to glial acidic fibrillary acidic protein. II. Titer of the antibody is detected in serum of patients with Alzheimer’s disease. Acta Neurrol Scand 90:554-560 (1999).
39. Sheffield WD, Kim SJ. Myelin basic protein causes proliferation of lymphocytes and astrocytes in vitro. Brain Res 122:509-517 (1977). 

40. Fabry J, Raines CS, Hart MN. Nervous tissue as an immune compartment: the dialogue of the immune response in the CNS. Immunol Today 15:218-221 (1994).
41. Kajiya Y, Tojo H, Kato F. Lymphocyte infiltration into normal rat brain following hypothermic brain-barrier opening. J Neuroimmunol 27:133-140 (1991).
42. Irani DN, Griffin DE. Isolation of brain parenchymal lymphocytes for flow cytometric analysis. J Immun Meth 133:223-231 (1991).
43. Hughes CC, Meak DL, Kantos PL. Adhesion of lymphocytes to cerebral microvascular cells: effects of interferon-y: tumor necrosis factor-l. Immunology 81:677-681 (1993).
44. Raines CS, Comella B, Devrinjtin AM, Ochs AH. Hemming to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial adhesion during the initial stages of autoimmune demyelination. Lab Invest 63:476-486 (1990).
45. Maule D, Pryce G, night, S. Lymphocyte migration into brain modelled in vitro: control by lymphocyte activation, cytokines and antigen. Cell Immunol 127:1-11 (1990).
46. Char WP, Jaworska T, Luke M. Infiltration of immune T cells in the brain of rats with herpes simplex virus-induced encephalitis. J Neuroimmunol 226:195-201 (1999).
47. Cash E, voest S, Voigt R, Kombuter H. Cells of cerebrospinal fluid of multiple sclerosis patients secrete antibodies to myelin basic protein in vitro. J Immunol 35:695-701 (1992).
48. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurocull 28:254-260 (1991).
49. Drachman DB, McIntosh KR, Del Silva S, Korn PW, Kahn C. Strepitococcus and myelitis in myasthenia gravis. Ann NY Acad Sci 540:176-188 (1989).
50. Hartung HP, Henninger K, Schaefer F, Frieh W, Toyka KV. Mechanisms in inflammatory polyneuropathy. Ann NY Acad Sci 540:122-161 (1989).
51. Tabira T. Autimmune demyelination in the central nervous system. Ann NY Acad Sci 540:181-201 (1989).
52. Nakamura K, Takeda M, Tanaka T, Tanaka J, Ito Y, Nishimura K, Nakamura T. Glial fibrillary acidic protein stimulates proliferation and immunoglobulin synthesis of lymphocytes from Alzheimer’s disease patients. Med Exp Clin Pharmacol 14:141-149 (1992).
53. Hart MN, Fabry J, CNS antigen presentation. TN 18:475-481 (1989).
54. Lowenthal A, Noppo M, Ohashi J, Kaufi J, Oulbe D, Libman (glial fibrillary acidic protein) in normal and pathological human brain and cerebrospinal fluid. J Neurol 219:87-91 (1978).
55. Cripps R, Noppo M, Caras J, Lowenthal A, Oulbe A (IGA) as a marker of astrocytic involvement in human cerebrospinal fluid. Neurochem Pathol 1:91-101 (1980).
56. Cripps R, Saegers J, Noppo M, Lowenthal A. Increased GFA levels in CSF as a marker of oncogenic involvement in patients with Alzheimer’s disease and other types of irreversible chronic organic brain dysfunction. J Neurol Sci 67:52-60 (1982).
57. Hantson MS, Merri CR. Cerebral fluid analysis in diseases of the nervous system. J Chronopathia 42:345-356 (1998).
58. Cohen SH, Herron RM, McAllister GM. Radiomimassay of cerebrospinal fluid. J Exp Med 294:1459-1467 (1979).
59. Vermytonk K. Determination of gliial fibrillary acidic protein, S100, myelin basic protein and neuron specific anaxin in cerebrospinal fluid from patients suffering from dementia (Letter). Acta Neurol Belg 88:318 (1988).
60. Noppo M, Libman (glial fibrillary acidic protein) in normal and pathological human brain and cerebrospinal fluid. J Neurol 219:87-91 (1978).
